LEADER 04893nam 2201213z- 450 001 9910580212703321 005 20231214133528.0 035 $a(CKB)5690000000011961 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/87484 035 $a(EXLCZ)995690000000011961 100 $a20202207d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aHospital Acquired Infections, Multidrug Resistant (MDR) Bacteria, Alternative Approaches to Antibiotic Therapy 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (206 p.) 311 $a3-0365-4418-6 311 $a3-0365-4417-8 330 $aBacterial resistance to known and currently used antibiotics represents a growing issue worldwide. It poses a major problem in the treatment of infectious diseases in general and hospital-acquired infections in particular. This is in part due to the overuse and misuse of antibiotics in past decades, which led to the selection of highly resistant bacteria and even so-called superbugs ? multidrug-resistant (MDR) bacteria. Nosocomial infections, particularly, are often caused by MDR bacterial pathogens and the treatment of such infections is very complicated and extensive, often leading to various side effects, including adverse effects on the natural human microbiome. At the same time, the development of novel antibiotics is lagging with very few new ones in the pipeline. Finding viable alternatives to treat such infections may help to overcome these therapeutic issues. This publication brings novel developments in the field of bacterial resistance, mainly in the hospital settings, adequate antibiotic therapy, and identification of compounds useful to battle this growing issue. 517 $aHospital Acquired Infections, Multidrug Resistant 606 $aMedicine$2bicssc 606 $aEpidemiology & medical statistics$2bicssc 610 $aVRE 610 $aGIT 610 $ahemato-oncological patients 610 $aclonality 610 $aantibiotic stewardship 610 $aresistance 610 $aconsumption of antibiotics 610 $aclonal spread 610 $aEnterococcus faecium 610 $aEnterococcus faecalis 610 $alinezolid resistance 610 $a23S rRNA 610 $aoptrA 610 $acarbapenem-resistant Klebsiella pneumoniae 610 $acarbapenem-resistant Acinetobacter baumannii 610 $aN-acetylcysteine 610 $aseptic shock 610 $acritically ill patients 610 $anewborn 610 $ainfection 610 $abacteria 610 $aantibiotic therapy 610 $ahops 610 $aC. difficile 610 $arat model 610 $aStaphylococcus aureus 610 $aMRSA 610 $aspa typing 610 $aMLST 610 $aSCCmec typing 610 $aclonal analysis 610 $aepidemiology 610 $acancer patients 610 $aduration of treatment 610 $acolistin 610 $apropensity score analysis 610 $amultidrug-resistant Acinetobacter baumannii 610 $aurinary tract infections 610 $aUTIs 610 $aMDR 610 $aEscherichia coli 610 $aKlebsiella 610 $auropathogens 610 $aAMR 610 $aantibiotic resistance 610 $aESBL-producing Klebsiella pneumoniae 610 $aurinary tract infection 610 $aclinical impact 610 $aeconomic impact 610 $aventilator-associated pneumonia 610 $aKlebsiella spp. 610 $aEscherichia spp. 610 $apulsed-field gel electrophoresis (PFGE) 610 $aendogenous infection 610 $amethicillin-resistant 610 $aporcine model 610 $amethicillin-resistant Staphylococcus aureus (MRSA) 610 $along term care facilities (LTCF) 610 $amultidrug resistance (MDR) 610 $aenterobacterial repetitive intergenic consensus-polymerase chain reaction (ERIC-PCR) 610 $aESBL 610 $aPCR 610 $aprimer 610 $aantimicrobial resistance 610 $ainfection prevention and control 610 $aantimicrobial stewardship 610 $ahospital 610 $acluster analysis 610 $aprincipal component analysis 615 7$aMedicine 615 7$aEpidemiology & medical statistics 700 $aBostik$b Pavel$4edt$01304524 702 $aKolar$b Milan$4edt 702 $aBostik$b Pavel$4oth 702 $aKolar$b Milan$4oth 906 $aBOOK 912 $a9910580212703321 996 $aHospital Acquired Infections, Multidrug Resistant (MDR) Bacteria, Alternative Approaches to Antibiotic Therapy$93027524 997 $aUNINA